HealthQuill Sweden
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
Sweden’s researchers have recorded 300 times higher methane emissions in open patches of Siljan Ring lakes, the largest meteorite crater in Europe, raising climate concerns.
Climate Health Research

Europe’s largest meteorite crater’s methane output remains a mystery

HQ Team April 10, 2025: Sweden’s researchers have recorded 300 times higher methane emissions in open patches of Siljan Ring lakes, the largest.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

Read More
The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are “miles away” from ensuring efficient preventive environments, according to a report from the independent Globsec.
Drugs Health Pharma

EU faces new healthcare threats, some states ‘miles away’ from ready 

The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are “miles away” from.

Read More
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
Drugs Health Pharma

AstraZeneca’s asthma drug gets regulator’s approval in China

China’s drug regulator, the National Medical Products Association, has approved  AstraZeneca Plc’s asthma drug.

Read More
German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a  vaccine for mpox.
Drugs Health Medical

Sweden confirms first case of Mpox outside Africa

HQ Team August 15, 2024: Sweden confirmed its first case of the most virulent form of Mpox Thursday, a viral infection found in.

Read More
The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed an extended nine months of survival.
Drugs Health Pharma

AstraZeneca’s medicine for non-small lung cancer gets EU nod

HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.

Read More
The USFDA has approved Calliditas Therapeutics’ oral drug to treat loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) and at risk of disease progression.
Drugs Health Pharma

Sweden’s Calliditas gets FDA nod for oral drug to treat kidney loss function

HQ Team December 21, 2023: Sweden’s Calliditas Therapeutics has got the USFDA green light for its oral drug to treat loss of kidney.

Read More
The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global health agency reported an 8.9% rise in global prevalence in cases arising in the UK, France and Sweden.
Drugs Health Pharma

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO 

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.

Read More